Is this you? Create Your Porfile
Avatar

Richard A. Larson

University of Maryland Marlene and Stewart Greenebaum Cancer Center

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Richard A. Larson is active.

Explore More

Publication

Featured researches published by Richard A. Larson.

Blood | 2008

Phase II Trial of Low Dose, Subcutaneous Decitabine in Myelofibrosis

Olatoyosi M Odenike; John E. Godwin; Koen van Besien; Dezheng Huo; Dorie Sher; Patrick Burke; Scott E. Smith; Margaret Green; Julia Melnick; James L Wade; Eric P. Lester; Rebecca B. Klisovic; Maria R. Baer; Richard A. Larson; Wendy Stock

ASCO Meeting Abstracts | 2014

Phase I study of Debio1143 (AT406) in combination with daunorubicin (D) and cytarabine (C) in patients with poor-risk acute myeloid leukemia (AML).

John F. DiPersio; Harry P. Erba; Richard A. Larson; Selina M. Luger; Kenneth Francis Mangan; Martin S. Tallman; Jeffrey Mark Brill; Grégoire Vuagniaux; Elisabeth Rouits; Claudio Zanna; J. Mel Sorensen

Archive | 2014

myeloid leukemia in chronic phase treated with frontline nilotinib or Early molecular response predicts outcomes in patients with chronic

Xiaolin Fan; Hans D. Menssen; Richard A. Larson; Andreas Hochhaus; Gianantonio Rosti; Chiaki Nakaseko; Carmino Antonio de Souza; Matt Kalaycio; Stephan Meier; Timothy Hughes; Giuseppe Saglio; Hagop M. Kantarjian; Francois Guilhot; D. Niederwieser; Raul C. Ribeiro

Archive | 2013

Group B Study 9222 myeloid leukemia in adults under 60 years of age: Cancer and Leukemia cytarabine alone as postremission intensification therapy for acute Sequential multiagent chemotherapy is not superior to high-dose

Charles A. Schiffer; Jonathan E. Kolitz; Maria R. Baer; Frederick R. Davey; Clara D. Bloomfield; Richard A. Larson; Joseph O. Moore; Stephen L. George; Richard K. Dodge; Philip C. Amrein; Bayard L. Powell

Archive | 2013

Leukemia Group B study myeloid leukemia and MLL partial tandem duplication: a Cancer and Long-term disease-free survivors with cytogenetically normal acute

Jonathan E. Kolitz; Richard A. Larson; Michael A. Caligiuri; Claudia D. Baldus; Jing Wen; Tamara Vukosavljevic; Bayard L. Powell; Andrew J. Carroll; Susan P. Whitman; Amy S. Ruppert; Guido Marcucci; Krzysztof Mrózek; Peter Paschka

Archive | 2013

leukemia Endpoints to establish the efficacy of new agents in the treatment of acute

Nancy S. Scher; Franklin O. Smith; Richard M. Stone; Martin S. Tallman; Stephen J. Forman; Richard A. Larson; Stephanie J. Lee; Sharon B. Murphy; Susan O'Brien; R. Appelbaum; Daniel Rosenblum; Robert J. Arceci; William L. Carroll; Philip P. Breitfeld

Archive | 2013

Group B Study leukemia patients with normal cytogenetics: a Cancer and Leukemia BAALC expression predicts clinical outcome of de novo acute myeloid

Joseph O. Moore; Richard A. Larson; Jonathan E. Kolitz; Michael A. Caligiuri; Andrew J. Carroll; James W. Vardiman; Bayard L. Powell; D. Baldus; Stephan M. Tanner; Amy S. Ruppert; Susan P. Whitman; Kellie J. Archer

Archive | 2013

study : Presented in part at the 43rd Annual Meeting of The American chronic myelogenous leukemia in myeloid blast crisis: results of a phase II Imatinib induces hematologic and cytogenetic responses in patients with

Ronald Paquette; Brian J. Druker; Christian Peschel; Gratwohl A; Franco Mandelli; Monique Ben-Am; Insa Gathmann; C. Shea; Chapuis B; Steven Coutre; Sante Tura; Enrica Morra; Richard A. Larson; S. G. O'Brien; Richard M. Stone; Carlo B. Gambacorti-Passerini; Nigel H. Russell; Jose Reiffers; Charles A. Schiffer; Moshe Talpaz; Francois Guilhot; Michael W. N. Deininger; L. Sawyers; Andreas Hochhaus; Eric J. Feldman; John M. Goldman; Carole B. Miller

Archive | 2013

myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study cytogenetically normal patients younger than 60 years with acute markers, poor outcome, and a distinct gene-expression signature in High BAALC expression associates with other molecular prognostic

L. Powell; Albert de la Chapelle; Jonathan E. Kolitz; Richard A. Larson; Guido Marcucci; Krzysztof Mrózek; Claudia D. Baldus; Tamara Vukosavljevic; Chang-Gong Liu; Mary E. Ross; Christian Langer; Michael D. Radmacher; Amy S. Ruppert; Susan P. Whitman; Peter Paschka

Archive | 2013

lymphoma: Cancer and Leukemia Group B study 19801 refractory T-lineage acute lymphoblastic leukemia or lymphoblastic Nelarabine induces complete remissions in adults with relapsed or

Jon P. Gockerman; Beverly S. Mitchell; Frederick R. Appelbaum; Richard A. Larson; Daniel J. DeAngelo; Daohai Yu; Jeffrey L. Johnson; Steven Coutre; Richard M. Stone

Explore More

Collaboration

Dive into the Richard A. Larson's collaboration.

Top Co-Authors
Avatar

Jonathan E. Kolitz

Hofstra University

View shared research outputs
Top Co-Authors
Avatar

Charles A. Schiffer

Wayne State University

View shared research outputs
Top Co-Authors
Avatar

Clara D. Bloomfield

Roswell Park Cancer Institute

View shared research outputs
Top Co-Authors
Avatar

Richard M. Stone

National Institutes of Health

View shared research outputs
Top Co-Authors
Avatar

Amy S. Ruppert

Ohio State University

View shared research outputs
Top Co-Authors
Avatar

Andrew J. Carroll

Ohio State University

View shared research outputs
Top Co-Authors
Avatar

Bayard L. Powell

Wake Forest Baptist Medical Center

View shared research outputs
Top Co-Authors
Avatar

Maria R. Baer

United States Department of Veterans Affairs

View shared research outputs
Top Co-Authors
Avatar

Francois Guilhot

Baylor College of Medicine

View shared research outputs
Top Co-Authors
Avatar

Frederick R. Davey

Syracuse University

View shared research outputs
Explore More
Researchain Logo
Decentralizing Knowledge